Articles related to SGLT2 INHIBITORS

Four major societies jointly published the first multidisciplinary guideline for cardiovascular-kidney-metabolic syndrome, introducing a standardized staging system and unified treatment framework across cardiology, nephrology, endocrinology, and primary care.

The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.

Large-scale propensity-matched analysis reveals differential cardiovascular outcomes between GLP-1 receptor agonists and SGLT-2 inhibitors in routine clinical practice.

SGLT2 inhibitors result in 300 calories of daily glucose elimination through urinary excretion, making dietary carbohydrate choices directly impact therapeutic effectiveness.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.